F S&P 500
5,558.50 +12.50 (+0.23%) F Dow Jones
39,528.00 -22.00 (-0.06%) F Nasdaq
20,121.50 +82.00 (+0.41%) E-mini Russell 2000 Index Futur
2,064.90 +4.80 (+0.23%) Petróleo
82.11 +0.37 (+0.45%) Oro
2,330.10 -6.50 (-0.28%)
Q BioMed Inc. (QBIO)
Q BioMed Inc.
366 Madison Avenue
3rd Floor
New York, NY 10017
United States
212 588 0022
https://www.qbiomed.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Denis D. Corin | Chairman, CEO & President | 300k | N/D | 1973 |
| Mr. William S. Rosenstadt | Chief Legal Officer, General Counsel & Director | 300k | N/D | 1968 |
| Mr. Ari Jatwes | Director of Finance | N/D | N/D | N/D |
Descripción
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Q BioMed Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
